Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt

EU orphan designation number: EU/3/11/888   
Active ingredient: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt
Indication: Treatment of primary myelofibrosis
Sponsor: Gilead Sciences International Limited
Granta Park, Abington, Cambridge CB21 6GT, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
09/08/2011 Centralised Orphan - Designation EMA/OD/152/10 (2011)5813 of 05/08/2011
17/02/2012 Centralised Orphan - Transfer of orphan designation EMEA/OD/152/10/T/01 (2012)1111 of 15/02/2012
21/05/2013 Centralised Orphan - Transfer of orphan designation EMA/OD/152/10/T/02 (2013)2934 of 15/05/2013